Home Newsfeeds JP Morgan Downgrades Dow to Neutral

JP Morgan Downgrades Dow to Neutral

JP Morgan analyst Jeffrey Zekauskas downgrades Dow (NYSE:DOW) from Overweight to Neutral.

byBenzinga Newsdesk

September 2, 2022

1 minute read

JP Morgan analyst Jeffrey Zekauskas downgrades Dow (NYSE:DOW) from Overweight to Neutral.

Mizuho Maintains Neutral on American Assets Trust, Lowers Price Target to $30

By Benzinga Newsdesk

July 27, 9:41 AM

Mizuho analyst Haendel St. Juste maintains American Assets Trust (NYSE:AAT) with a Neutral and lowers the price target from $37 to $30.

AAT

K36 Therapeutics Announces $70M Series B Financing To Fund Clinical Proof Of Concept Of KTX-1001, First-In-Class Inhibitor Of MMSET For Treatment Of Multiple Myeloma Patients With Genetic Translocation (4;14)

By Happy Mohamed

June 28, 8:14 AM

Funds raised will be used to demonstrate clinical validation and proof-of-concept in t(4;14) multiple myeloma with KTX-1001 monotherapy and KTX-1001 combination regimens with existing standard-of-care

BMY

Truist Securities Maintains Buy on Spotify Technology, Raises Price Target to $132

By Benzinga Newsdesk

February 2, 8:24 AM

Truist Securities analyst Matthew Thornton maintains Spotify Technology (NYSE:SPOT) with a Buy and raises the price target from $115 to $132.

SPOT

FDA Approves Teva/MedinCell’s Antipsychotic Injection For Adult Schizophrenia Patients

By Vandana Singh

May 1, 8:38 AM

The FDA has approved Teva Pharmaceuticals Industries Ltd (NYSE:TEVA) and MedinCell’s approved Uzedy (risperidone) extended-release injectable suspension for schizophrenia in adults. …

TEVA

JP Morgan Downgrades Dow to Neutral

Related Posts

Mizuho Maintains Neutral on American Assets Trust, Lowers Price Target to $30

K36 Therapeutics Announces $70M Series B Financing To Fund Clinical Proof Of Concept Of KTX-1001, First-In-Class Inhibitor Of MMSET For Treatment Of Multiple Myeloma Patients With Genetic Translocation (4;14)

Truist Securities Maintains Buy on Spotify Technology, Raises Price Target to $132

FDA Approves Teva/MedinCell’s Antipsychotic Injection For Adult Schizophrenia Patients